Cravath’s New York Office Moves to Two Manhattan West
Joyce Law is a senior attorney in Cravath’s Corporate Department, with concentration in the real estate practice area. Ms. Law’s experience includes real estate development, acquisitions and dispositions, as well as real estate financing, including fund credit facilities and municipal financings, real estate fund work, and leasing transactions.
Ms. Law also regularly assists on the real estate aspects of various corporate mergers and acquisitions.
Ms. Law’s clients have included Morgan Stanley, IBM, Kraft Foods Inc., Bristol‑Myers Squibb Company, Unilever, Jones Apparel Group, Inc., Westbrook Partners and The Dermot Company, Inc.
Ms. Law was born in Rapid City, South Dakota. She received a Bachelor of Commerce with distinction from the University of Alberta in 1994 and a J.D. from Boston University in 1997. Ms. Law joined Cravath in 2001 and was elected a senior attorney in 2015. Prior to joining Cravath, she was associated with a real estate developer in New York.
Ms. Law also regularly assists on the real estate aspects of various corporate mergers and acquisitions.
Ms. Law’s clients have included Morgan Stanley, IBM, Kraft Foods Inc., Bristol‑Myers Squibb Company, Unilever, Jones Apparel Group, Inc., Westbrook Partners and The Dermot Company, Inc.
Ms. Law was born in Rapid City, South Dakota. She received a Bachelor of Commerce with distinction from the University of Alberta in 1994 and a J.D. from Boston University in 1997. Ms. Law joined Cravath in 2001 and was elected a senior attorney in 2015. Prior to joining Cravath, she was associated with a real estate developer in New York.
Deals & Cases
May 28, 2024
On May 28, 2024, United States Cellular Corporation (“UScellular”) announced that it has entered into a definitive agreement to sell its wireless operations and select spectrum assets to T‑Mobile for a purchase price of $4.4 billion, including a combination of cash and up to approximately $2 billion of assumed debt. Under the terms of the agreement, T‑Mobile will acquire UScellular’s wireless operations and approximately 30% of its spectrum assets across several spectrum bands. In addition, T‑Mobile will enter into a new master license agreement with UScellular on more than 2,000 towers. The agreement follows a thorough strategic review process announced in August 2023 and has been unanimously recommended by the independent directors of UScellular and unanimously approved by the Board of Directors of UScellular. Cravath is representing the independent directors of UScellular in connection with the transaction.
Deals & Cases
May 07, 2024
On May 7, 2024, Ashland Inc. (“Ashland”), a global additives and specialty ingredients company, announced that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC. Cravath is representing Ashland in connection with the transaction.
Deals & Cases
April 02, 2024
On April 2, 2024, Endeavor Group Holdings, Inc. (“Endeavor”), a global sports and entertainment company, announced that it has entered into a definitive agreement to be acquired by Silver Lake, the global leader in technology investing, in partnership with the Endeavor management team and additional anchor investors. Cravath is representing the independent Special Committee of Endeavor’s board of directors in connection with the transaction.
Deals & Cases
March 22, 2024
On March 21, 2024, ECN Capital Corp. (“ECN Capital”), a leading provider of business services to North American based banks, credit unions, life insurance companies, pension funds and institutional investors, announced the sale of Red Oak Inventory Finance (“Red Oak”) to BharCap Partners, a private investment firm. The transaction closed on February 21, 2024. Cravath represented ECN Capital in connection with the transaction.
Deals & Cases
February 12, 2024
On February 12, 2024, CymaBay Therapeutics (“CymaBay”) and Gilead Sciences, Inc. (“Gilead”) announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis, complements Gilead’s existing liver portfolio and aligns with its longstanding commitment to bringing transformational medicines to patients. Cravath is representing CymaBay in connection with the transaction.
Joyce Law is a senior attorney in Cravath’s Corporate Department, with concentration in the real estate practice area. Ms. Law’s experience includes real estate development, acquisitions and dispositions, as well as real estate financing, including fund credit facilities and municipal financings, real estate fund work, and leasing transactions.
Ms. Law also regularly assists on the real estate aspects of various corporate mergers and acquisitions.
Ms. Law’s clients have included Morgan Stanley, IBM, Kraft Foods Inc., Bristol‑Myers Squibb Company, Unilever, Jones Apparel Group, Inc., Westbrook Partners and The Dermot Company, Inc.
Ms. Law was born in Rapid City, South Dakota. She received a Bachelor of Commerce with distinction from the University of Alberta in 1994 and a J.D. from Boston University in 1997. Ms. Law joined Cravath in 2001 and was elected a senior attorney in 2015. Prior to joining Cravath, she was associated with a real estate developer in New York.
Ms. Law also regularly assists on the real estate aspects of various corporate mergers and acquisitions.
Ms. Law’s clients have included Morgan Stanley, IBM, Kraft Foods Inc., Bristol‑Myers Squibb Company, Unilever, Jones Apparel Group, Inc., Westbrook Partners and The Dermot Company, Inc.
Ms. Law was born in Rapid City, South Dakota. She received a Bachelor of Commerce with distinction from the University of Alberta in 1994 and a J.D. from Boston University in 1997. Ms. Law joined Cravath in 2001 and was elected a senior attorney in 2015. Prior to joining Cravath, she was associated with a real estate developer in New York.
Deals & Cases
May 28, 2024
On May 28, 2024, United States Cellular Corporation (“UScellular”) announced that it has entered into a definitive agreement to sell its wireless operations and select spectrum assets to T‑Mobile for a purchase price of $4.4 billion, including a combination of cash and up to approximately $2 billion of assumed debt. Under the terms of the agreement, T‑Mobile will acquire UScellular’s wireless operations and approximately 30% of its spectrum assets across several spectrum bands. In addition, T‑Mobile will enter into a new master license agreement with UScellular on more than 2,000 towers. The agreement follows a thorough strategic review process announced in August 2023 and has been unanimously recommended by the independent directors of UScellular and unanimously approved by the Board of Directors of UScellular. Cravath is representing the independent directors of UScellular in connection with the transaction.
Deals & Cases
May 07, 2024
On May 7, 2024, Ashland Inc. (“Ashland”), a global additives and specialty ingredients company, announced that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC. Cravath is representing Ashland in connection with the transaction.
Deals & Cases
April 02, 2024
On April 2, 2024, Endeavor Group Holdings, Inc. (“Endeavor”), a global sports and entertainment company, announced that it has entered into a definitive agreement to be acquired by Silver Lake, the global leader in technology investing, in partnership with the Endeavor management team and additional anchor investors. Cravath is representing the independent Special Committee of Endeavor’s board of directors in connection with the transaction.
Deals & Cases
March 22, 2024
On March 21, 2024, ECN Capital Corp. (“ECN Capital”), a leading provider of business services to North American based banks, credit unions, life insurance companies, pension funds and institutional investors, announced the sale of Red Oak Inventory Finance (“Red Oak”) to BharCap Partners, a private investment firm. The transaction closed on February 21, 2024. Cravath represented ECN Capital in connection with the transaction.
Deals & Cases
February 12, 2024
On February 12, 2024, CymaBay Therapeutics (“CymaBay”) and Gilead Sciences, Inc. (“Gilead”) announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis, complements Gilead’s existing liver portfolio and aligns with its longstanding commitment to bringing transformational medicines to patients. Cravath is representing CymaBay in connection with the transaction.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.